retatrutide type 2 diabetes phase 2 results 2024 Effects of on body composition in people with diabetes: a substudy of a 2, double-blind, parallel-group, placebo-controlled, randomised trial Media Centre | EASD

CrossRef Robust HLA-B-restricted CD8+ T-cell responses in chronic HBV infection Julia Lang-Meli, Anna-Lena Denecke, Johannes Ptok, Philipp Ehrenmann, Elahe Salimi Alizei, Hendrik Luxenburger, Michelle Maas, Muthamia Kiraithe, Felix Jacobi, Giuseppe Rusignuolo, Isabel Schulien, Emma Gostick, Sian Llewellyn-Lacey, Florian Emmerich, Ber JHEP Reports .2026

Healthcare providers are increasingly prioritizing treatment approaches that address not only blood glucose control but also associated comorbidities such as obesity and cardiovascular disease

CMS will collect utilization data from the Bridge to share with Part D plan sponsors ahead of a potential future BALANCE implementation

Phase 2 trial data (NEJM 2023) showed approximately 17.5% mean body weight reduction at 24 weeks at the highest dose, but week-4 figures were not reported as a primary endpoint

Approval or denial: Once reviewed, the insurance company will either approve or deny the request

This enables a semi-permanent, just-eaten sensation of fullness that consequently leads to decreased food intake and, ultimately, weight loss